Key Takeaways
AIM ImmunoTech Inc. (NYSE American: AIM) reported a 50 percent objective response rate from its Phase 2 study of Ampligen (rintatolimod) in combination with Merck’s Keytruda (pembrolizumab) and cisplatin for recurrent ovarian cancer. The data suggests the treatment combination holds breakthrough potential in a difficult-to-treat patient population.
"The addition of IP Ampligen and systemic PD-1 checkpoint inhibition to IP cisplatin chemotherapy resulted in a significant improvement in both clinical response rates and immune activation," Robert P. Edwards, MD, of the University of Pittsburgh School of Medicine, said in a statement. The trial was supported by a grant from Merck.
The final report from the single-arm UPMC trial detailed a 50 percent objective response rate, which included a 21 percent rate of complete responses where no detectable cancer remained. The clinical benefit rate was 79 percent, with a median overall survival of 32.5 months. Notably, the company reported durable responses exceeding 70 months in select patients and no Grade 4 or 5 toxicities were observed.
Despite the positive clinical data, shares of AIM ImmunoTech fell 6.96 percent on the day of the announcement. The reaction fits a pattern of volatility for the stock, which has historically seen both sharp gains and notable selloffs following clinical trial updates. The company has an effective S-3 shelf registration, allowing it to raise up to $100 million, which may present ongoing dilution risk for investors.
AIM’s CEO, Thomas K. Equels, said the results suggest Ampligen may "unlock the full potential of checkpoint immunotherapies" across multiple cancer types, including pancreatic cancer. The company highlighted its intellectual property protection for Ampligen extending into 2039.
The trial’s positive outcome provides a key clinical proof-of-concept for Ampligen’s mechanism. Investors and clinicians will now look toward the collection of secondary endpoint data, including progression-free survival, which is expected in January 2027. This future data will be critical for designing a potential Phase 3 study and further validating the therapy’s role.
This article is for informational purposes only and does not constitute investment advice.
